SCHEMBL1104802

SCHEMBL1104802

c1ccc2cn3ccnc3cc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 3/20 0.45
KEAP1 Q14145 1/20 0.42
TGFBR1 P36897 3/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
KMT2A Q03164 1/20 0.40
FAAH O00519 1/20 0.36
MAPK9 P45984 1/20 0.35
MAPK10 P53779 1/20 0.35
PIK3CA P42336 1/20 0.35
TRIM33 Q9UPN9 2/20 0.34
CHEK1 O14757 1/20 0.34
MAP4K4 O95819 1/20 0.34
CSF1R P07333 1/20 0.34
PRKACA P17612 1/20 0.34
KDR P35968 1/20 0.34
CDK8 P49336 1/20 0.34
MAP2K1 Q02750 1/20 0.34
ACVR1 Q04771 1/20 0.34
MAP4K2 Q12851 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15909593 0.79 NPC1 (0.44) DYRK1AKEAP1TGFBR1MEN1CYP1A2
SCHEMBL21530593 0.75 KDM4E (0.50) DYRK1AKEAP1TGFBR1MEN1CYP1A2
SCHEMBL21161402 0.70 RAB9A (0.51) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL29605597 0.68 AHR (0.48) KMT2ASMN1; SMN2KDM4EALDH1A1
SCHEMBL8642940 0.68 DNMT1 (0.40) MAPK9MAPK10KDRSMN1; SMN2RET
SCHEMBL9611716 0.68 CYP1A2 (0.41) CYP1A2KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL268000 0.67
SCHEMBL7883 0.67
SCHEMBL21593291 0.67 LTA4H (0.41) FAAHKDRNPC1RAB9ASMN1; SMN2
SCHEMBL24231953 0.67 TGFBR1 (0.43) DYRK1AKEAP1TGFBR1MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12022728-B2 Organic electroluminescent element and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2024-06-25 US disclosed
US-20230242556-A1 NOVEL METHOD FOR MANUFACTURING DEUTERATED BORON COMPOUND SFC CO., LTD. (KR) 2023-08-03 US disclosed
US-20230242556-A1 NOVEL METHOD FOR MANUFACTURING DEUTERATED BORON COMPOUND SFC CO., LTD. (KR) 2023-08-03 US disclosed
US-11691983-B2 Specifically substituted benzofuro- and benzothienoquinolines for organic light emitting diodes IDEMITSU KOSAN CO., LTD. (JP) 2023-07-04 US disclosed
US-11672172-B2 Heterocyclic compound comprising aromatic amine group and organic light-emitting diode including the same SFC CO., LTD. (KR) 2023-06-06 US disclosed
US-11672172-B2 Heterocyclic compound comprising aromatic amine group and organic light-emitting diode including the same SFC CO., LTD. (KR) 2023-06-06 US disclosed
US-20230002419-A1 NOVEL BORON COMPOUND AND ORGANIC LIGHT EMITTING DIODE INCLUDING SAME SFC CO., LTD. (KR) 2023-01-05 US disclosed
US-11482676-B2 Light emitting diode including boron compound SFC CO., LTD. (KR) 2022-10-25 US disclosed
US-20210036233-A1 LIGHT EMITTING DIODE INCLUDING BORON COMPOUND SFC CO., LTD. (KR) 2021-02-04 US disclosed
US-10763442-B2 Compound, organic electroluminescent element material using same, organic electroluminescent element using this material, and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2020-09-01 US disclosed
US-20070232618-A1 Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands WYETH (US) 2007-10-04 US disclosed
US-7271180-B2 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2007-09-18 US disclosed
US-7259165-B2 Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2007-08-21 US disclosed
US-7238696-B2 Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands WYETH (US) 2007-07-03 US disclosed
US-7220756-B2 N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2007-05-22 US disclosed
WO-2007032833-A1 AZINYL-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2007-03-22 WO disclosed
US-20070054896-A1 Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders WYETH (US) 2007-03-08 US disclosed
WO-2007021711-A2 SUBSTITUTED-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2007-02-22 WO disclosed
US-20070037802-A1 such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders WYETH (US) 2007-02-15 US disclosed
US-20040167122-A1 Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands WYETH 2004-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232618-A1 Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands HTR6, HTR2C, HTR3B DYRK1A 2349/4885KEAP1 1712/4885TGFBR1 2739/4885
US-20230002419-A1 NOVEL BORON COMPOUND AND ORGANIC LIGHT EMITTING DIODE INCLUDING SAME CLTB, CD79B, RB1 DYRK1A 1747/4885KEAP1 1684/4885TGFBR1 2568/4885
US-11691983-B2 Specifically substituted benzofuro- and benzothienoquinolines for organic light emitting diodes KCNQ2, KCNQ1, KCNQ4 DYRK1A 3876/4885KEAP1 1306/4885TGFBR1 741/4885
US-20070037802-A1 such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders HTR6, TPH1, HTR1A DYRK1A 1900/4885KEAP1 1420/4885TGFBR1 3212/4885
US-20040167122-A1 Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands HTR6, HTR1A, HTR2C DYRK1A 2522/4885KEAP1 1549/4885TGFBR1 2191/4885
US-20230242556-A1 NOVEL METHOD FOR MANUFACTURING DEUTERATED BORON COMPOUND BCL6B, BRD7, DBF4 DYRK1A 263/4885KEAP1 1557/4885TGFBR1 4581/4885
US-10763442-B2 Compound, organic electroluminescent element material using same, organic electroluminescent element using this material, and electronic device OR10J3, RER1, L1CAM DYRK1A 4428/4885KEAP1 1842/4885TGFBR1 2804/4885
US-12022728-B2 Organic electroluminescent element and electronic device L1CAM, ESR1, LEF1 DYRK1A 4125/4885KEAP1 693/4885TGFBR1 1313/4885
US-20070054896-A1 Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders HTR6, HTR1A, HTR3B DYRK1A 2047/4885KEAP1 1078/4885TGFBR1 3531/4885
US-11672172-B2 Heterocyclic compound comprising aromatic amine group and organic light-emitting diode including the same DDC, TYR, AOC2 DYRK1A 2568/4885KEAP1 494/4885TGFBR1 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.